Othera Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Othera Pharmaceuticals's estimated annual revenue is currently $6.2M per year.
- Othera Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Othera Pharmaceuticals has 31 Employees.
- Othera Pharmaceuticals grew their employee count by 48% last year.
Othera Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $40.6M | 202 | -2% | N/A | N/A |
#2 | $74.6M | 371 | 19% | N/A | N/A |
#3 | $11.7M | 58 | 14% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.4M | 221 | -2% | N/A | N/A |
#6 | $12.5M | 62 | 7% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $18.3M | 91 | 6% | N/A | N/A |
#9 | $59.9M | 298 | 23% | N/A | N/A |
#10 | $12.9M | 64 | 10% | N/A | N/A |
What Is Othera Pharmaceuticals?
Othera is a pharmaceutical company developing novel therapeutics for age-related diseases of the eye. Othera's lead compound, OT-551 is an eye drop in a Phase II clinical trial for the dry form of macular degeneration (AMD), and recently announced positive interim data from that trial, with full trial results due in mid-2010. The company is also developing novel treatments for glaucoma and neurodegenerative diseases.
keywords:N/AN/A
Total Funding
31
Number of Employees
$6.2M
Revenue (est)
48%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Othera Pharmaceuticals News
In 2020 Collaborations Pharmaceuticals, a company that specializes in looking ... including not only VX but other known chemical weapons,...
One colonoscopy used AI; the other, a standard colonoscopy, did not. ... Cosmo Pharmaceuticals, Fujifilm, Olympus and Virgo.
The other, a phase 1/2 trial led by Alberta Health Service, is looking at the ... pharmaceutical industry to accelerate data science driven drug discovery.
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.2M | 31 | 11% | N/A |
#2 | $8M | 32 | 14% | N/A |
#3 | $15M | 32 | -9% | N/A |
#4 | $6.6M | 33 | -44% | N/A |
#5 | $9.2M | 35 | 6% | N/A |